Company intelligence / Profile preview

Advanced Perfusion Diagnostics

Ownership: Private
Development stage: Commercial

Overview

APD developed IKORUS, a CE-marked single-use medical device for continuous, real-time assessment of visceral microvascular perfusion. The technology aimed to detect early signs of sepsis and organ dysfunction before conventional tests or clinical symptoms appeared. The product underwent pre-clinical validation, First-in-Man trials, and received CE mark in 2016 before being acquired by Vygon Group in 2019–2020.

Therapeutic areas: OtherInfectious Diseases
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Not specified; post-acquisition integration with Vygon’s critical care business unit.

Beyond the preview

Go deeper on Advanced Perfusion Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Perfusion Diagnostics.

Explore the full profile